AR051009A1 - Formulaciones de estabilizacion de proteinas - Google Patents
Formulaciones de estabilizacion de proteinasInfo
- Publication number
- AR051009A1 AR051009A1 ARP050103456A ARP050103456A AR051009A1 AR 051009 A1 AR051009 A1 AR 051009A1 AR P050103456 A ARP050103456 A AR P050103456A AR P050103456 A ARP050103456 A AR P050103456A AR 051009 A1 AR051009 A1 AR 051009A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- formulation
- suffractant
- storing
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Las formulaciones descritas son adecuadas para el almacenamiento de proteínas, tal como los anticuerpos, sobre, relativamente, una escala ancha de concentraciones de proteínas, pH, y tipos de tampones. También están descritos los métodos de almacenar una proteína y métodos de identificación de una formulación adecuada para el almacenamiento de una proteína específica. En general, una formulación contiene una cantidad baja o ningún sufractante, nada o una concentración relativamente baja de sal, y requiere e una concentración baja de tampón. Reivindicación 1: Una formulación incluyendo (a) una proteína aislada; y (b) una solución acuosa que tiene un pH de 4.0 a pH 8.0, en qué la formulación contiene un crioprotectante o sufractante, y la proteína es estable por un período de tiempo de no menos de 3 semanas a una temperatura entre -80°C a 8°C. Reivindicación 49: Un polipéptido producido por un método que incluye almacenamiento en una formulación de la afirmación 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60131104P | 2004-08-13 | 2004-08-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR051009A1 true AR051009A1 (es) | 2006-12-13 |
Family
ID=35908214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050103456A AR051009A1 (es) | 2004-08-13 | 2005-08-16 | Formulaciones de estabilizacion de proteinas |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8871201B2 (es) |
| EP (1) | EP1784219B1 (es) |
| JP (1) | JP4948407B2 (es) |
| KR (1) | KR20070092197A (es) |
| CN (1) | CN101022831A (es) |
| AR (1) | AR051009A1 (es) |
| AU (1) | AU2005272603A1 (es) |
| BR (1) | BRPI0514340A (es) |
| CA (1) | CA2575870A1 (es) |
| CR (1) | CR8904A (es) |
| EC (1) | ECSP077246A (es) |
| ES (1) | ES2637854T3 (es) |
| IL (1) | IL181265A0 (es) |
| MX (1) | MX2007001599A (es) |
| NO (1) | NO20070930L (es) |
| RU (1) | RU2007109062A (es) |
| TW (1) | TW200621282A (es) |
| WO (1) | WO2006020935A2 (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| SG162788A1 (en) | 2005-06-14 | 2010-07-29 | Amgen Inc | Self-buffering protein formulations |
| US20080003220A1 (en) * | 2006-04-21 | 2008-01-03 | Amgen, Inc. | Buffering agents for biopharmaceutical formulations |
| AR060487A1 (es) * | 2006-04-21 | 2008-06-18 | Xoma Technology Ltd | Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40 |
| US20080070230A1 (en) * | 2006-06-12 | 2008-03-20 | Wyeth | Methods for reducing or preventing liquid-liquid phase separation in high concentration protein solutions |
| EP1950225A1 (de) * | 2007-01-25 | 2008-07-30 | Octapharma AG | Verfahren zur Steigerung von Proteinausbeuten |
| JP2010522752A (ja) | 2007-03-29 | 2010-07-08 | アボット・ラボラトリーズ | 結晶性抗ヒトｉｌ−１２抗体 |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| KR20150080038A (ko) * | 2007-11-30 | 2015-07-08 | 애브비 바이오테크놀로지 리미티드 | 단백질 제형 및 이의 제조방법 |
| CN102301235B (zh) * | 2008-11-28 | 2014-11-19 | Abbvie公司 | 稳定的抗体组合物和用于稳定其的方法 |
| US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
| EP2403873A1 (en) | 2009-03-05 | 2012-01-11 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
| AU2010246168A1 (en) * | 2009-05-04 | 2011-11-10 | Abbvie Biotechnology Ltd | Stable high protein concentration formulations of human anti-TNF-alpha-antibodies |
| EP2473527B1 (en) | 2009-09-03 | 2016-11-30 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
| JP6463968B2 (ja) | 2011-07-01 | 2019-02-06 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | アルギニンを含まない腫瘍壊死因子受容体：ｆｃ融合ポリペプチド組成物およびその使用方法 |
| BR112014013099A8 (pt) | 2011-11-30 | 2023-05-09 | 3M Innovative Properties Company | Dispositivo de microagulhas incluindo um agente terapêutico peptídeo e um aminoácido e métodos para produzir e usar o dispositivo |
| JP6265970B2 (ja) * | 2012-03-26 | 2018-01-24 | サノフイ | 安定なＩｇＧ４に基づく結合剤の製剤 |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| EP2934587A4 (en) * | 2012-12-18 | 2016-08-03 | Merck Sharp & Dohme | Liquid formulations for an anti-TNF-alpha-antibody |
| WO2015065954A1 (en) | 2013-11-04 | 2015-05-07 | Pfizer, Inc. | Anti-efna4 antibody-drug conjugates |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| CA2955607A1 (en) * | 2014-07-21 | 2016-01-28 | Unchained Labs | Determination of protein aggregation from the concentration dependence of delta g |
| MX2017013801A (es) | 2015-04-29 | 2018-08-15 | Radius Pharmaceuticals Inc | Métodos para tratar el cáncer. |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| DK3761035T3 (da) * | 2016-08-18 | 2024-03-11 | Regeneron Pharma | Analyse til bestemmelse af et proteins potentiale til selvassociering ved hjælp af koncentrationsafhængig selvinteraktionsnanopartikelspektroskopi |
| MX2019004580A (es) | 2016-10-21 | 2019-08-12 | Amgen Inc | Formulaciones farmaceuticas y metodos para prepararlas. |
| IL292245B1 (en) | 2017-01-05 | 2024-12-01 | Radius Pharmaceuticals Inc | Polymorphic forms of rad1901-2hcl |
| WO2020010216A1 (en) | 2018-07-04 | 2020-01-09 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad 1901-2hcl |
| EP4279066A4 (en) * | 2021-01-14 | 2024-11-20 | Hanall Biopharma Co., Ltd. | OPHTHALMIC COMPOSITION COMPRISING TANFANERCEPT AND HAVING STABILITY WITHOUT THE USE OF A STABILIZER |
| CN115541895B (zh) * | 2022-11-29 | 2023-05-19 | 天津德祥生物技术股份有限公司 | 一种提高微流控反定检测卡灵敏度的配方液及应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3176517D1 (en) * | 1980-04-24 | 1987-12-17 | Beecham Group Plc | Beta-lactam compounds, their preparation and use |
| GB8518416D0 (en) | 1985-07-22 | 1985-08-29 | Beecham Group Plc | Compounds |
| US5869053A (en) * | 1988-03-04 | 1999-02-09 | Cancer Research Campaign Technology, Ltd. | 5T4 antigen from human trophoblasts |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| EP1012259B1 (en) * | 1997-06-04 | 2009-09-30 | Oxford Biomedica (UK) Limited | Tumor targeted vector |
| IL133220A0 (en) * | 1997-06-13 | 2001-03-19 | Genentech Inc | Stabilized antibody formulation |
| AU2444899A (en) | 1998-01-22 | 1999-08-09 | Astrazeneca Ab | Pharmaceutical formulation comprising an antibody and a citrate buffer |
| JP4516711B2 (ja) * | 1999-12-28 | 2010-08-04 | 中外製薬株式会社 | 安定な抗体組成物及び注射製剤 |
| ES2644275T3 (es) * | 2000-08-11 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Preparaciones estabilizadas que contienen anticuerpos |
| IL155002A0 (en) * | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
| GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| NZ533657A (en) * | 2002-01-03 | 2008-01-31 | Smithkline Beecham Corp | Methods for the preparation of immunoconjugates, in particular maytansinoids conjugated to a monoclonal antibody |
| ES2545745T3 (es) * | 2002-05-02 | 2015-09-15 | Wyeth Holdings Llc | Conjugados de transportador derivado de caliqueamicina |
| EP1551875A4 (en) * | 2002-06-21 | 2006-06-28 | Biogen Idec Inc | TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| CA2535804A1 (en) | 2003-08-14 | 2005-03-03 | Wyeth | Anti-lewis y anti-idiotypic antibodies and uses thereof |
| GT200500255A (es) | 2004-09-10 | 2006-04-10 | Anticuerpos anti-5ta humanizados y conjugados anticuerpo anti-5ta/calicheamicina |
-
2005
- 2005-08-11 TW TW094127308A patent/TW200621282A/zh unknown
- 2005-08-12 EP EP05803522.1A patent/EP1784219B1/en active Active
- 2005-08-12 US US11/203,367 patent/US8871201B2/en active Active
- 2005-08-12 ES ES05803522.1T patent/ES2637854T3/es active Active
- 2005-08-12 KR KR1020077003502A patent/KR20070092197A/ko not_active Application Discontinuation
- 2005-08-12 CA CA002575870A patent/CA2575870A1/en not_active Abandoned
- 2005-08-12 WO PCT/US2005/028861 patent/WO2006020935A2/en active Application Filing
- 2005-08-12 CN CNA2005800274833A patent/CN101022831A/zh active Pending
- 2005-08-12 JP JP2007525855A patent/JP4948407B2/ja active Active
- 2005-08-12 BR BRPI0514340-3A patent/BRPI0514340A/pt not_active IP Right Cessation
- 2005-08-12 RU RU2007109062/13A patent/RU2007109062A/ru not_active Application Discontinuation
- 2005-08-12 MX MX2007001599A patent/MX2007001599A/es unknown
- 2005-08-12 AU AU2005272603A patent/AU2005272603A1/en not_active Abandoned
- 2005-08-16 AR ARP050103456A patent/AR051009A1/es unknown
-
2007
- 2007-02-06 CR CR8904A patent/CR8904A/es not_active Application Discontinuation
- 2007-02-11 IL IL181265A patent/IL181265A0/en unknown
- 2007-02-13 EC EC2007007246A patent/ECSP077246A/es unknown
- 2007-02-19 NO NO20070930A patent/NO20070930L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101022831A (zh) | 2007-08-22 |
| RU2007109062A (ru) | 2008-09-20 |
| EP1784219B1 (en) | 2017-05-17 |
| US8871201B2 (en) | 2014-10-28 |
| CA2575870A1 (en) | 2006-02-23 |
| TW200621282A (en) | 2006-07-01 |
| ES2637854T3 (es) | 2017-10-17 |
| ECSP077246A (es) | 2007-05-30 |
| KR20070092197A (ko) | 2007-09-12 |
| AU2005272603A1 (en) | 2006-02-23 |
| WO2006020935A2 (en) | 2006-02-23 |
| NO20070930L (no) | 2007-05-14 |
| MX2007001599A (es) | 2007-04-10 |
| BRPI0514340A (pt) | 2008-06-10 |
| EP1784219A4 (en) | 2010-02-17 |
| CR8904A (es) | 2007-08-28 |
| IL181265A0 (en) | 2007-07-04 |
| EP1784219A2 (en) | 2007-05-16 |
| WO2006020935A3 (en) | 2007-03-08 |
| US20060115472A1 (en) | 2006-06-01 |
| JP2008515775A (ja) | 2008-05-15 |
| JP4948407B2 (ja) | 2012-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR051009A1 (es) | Formulaciones de estabilizacion de proteinas | |
| AR083034A1 (es) | ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO | |
| JP2017222654A5 (es) | ||
| CO2019011463A2 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas | |
| PE20070796A1 (es) | Metodo de produccion proteica utilizando compuestos anti-senescencia | |
| PE20070437A1 (es) | FORMULACION ACUOSA hFSH | |
| ECSP088109A (es) | Composición agrícola | |
| BR112013013902A2 (pt) | processo para tratar uma formação de arenito, fluido adequado para uso no processo e kit de partes | |
| AR098880A2 (es) | Solución protectora para prevenir daños isquémicos en los órganos o en sistemas celulares aislados o en componentes de tejido después de la perfusión, operación, transplante o crio-conservación y subsiguiente reperfusión | |
| ATE406102T1 (de) | Verfahren zur konservierung von frischen produkte und dafür geeignete überzugsmischung | |
| CO5601047A2 (es) | Metodo de cultivo celular libre de animal | |
| Li et al. | Sperm proteins in teleostean and chondrostean (sturgeon) fishes | |
| CL2010001070A1 (es) | Mezclas herbicidas sinérgicas que comprende picolinafen y un segundo compuesto selecto entre cuatro subgrupos de sulfonilureas y opcionalmente un antídoto;composición que comprende dicha mezcla herbicida junto a un soporte liquido y/o sólido y método que las emplea para combatir vegetación no deseada .solic.div .de 522-2004 | |
| CO2021015561A2 (es) | Formulaciones de anticuerpo de baja viscosidad, estables y usos de las mismas | |
| ES2229931B1 (es) | Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos. | |
| EA201691066A1 (ru) | Растворы для повышения стабильности и срок годности раствора для консервирования органов и тканей | |
| CO5320611A1 (es) | Una composicion para extraer sales metalicas divalentes, un metodo para prepararla y su uso para reducir los depositos de sales metalicas divalentes en un sistema acuoso | |
| Lee et al. | Cryopreservation of Korean Oge chicken semen using N-methylacetamide | |
| CO2022005737A2 (es) | Formulación estable de anticuerpo de integrina | |
| ECSP045101A (es) | Metodo para controlar nematodos parasitos de plantas dañinos | |
| Strzeżek et al. | Effect of different egg yolk sources on dog semen quality following cryopreservation | |
| JP2010091398A (ja) | 安定なナトリウム利尿ペプチド組成物 | |
| PE20090460A1 (es) | Metodo para separar microorganismos adheridos a una muestra solida, mediante el uso de un amortiguador en base a fosfato y sonicacion de la muestra | |
| BRPI0012150B8 (pt) | processo para estabilizar proteínas em misturas complexas na armazenagem em solventes aquosos, bem como de preparação de uma proteína heteróloga | |
| Shaluei et al. | Optimization Protocol for Storage of Goldfish (C arassius auratus) Embryos in Chilled State |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |